Golden Helix Announces VSClinical

Clinical Interpretation of Variants Based on ACMG Guidelines

Press Release ( - BOZEMAN, Mont. - Apr 10, 2018 - Golden Helix has announced the upcoming release of VSClinical, the company’s newest software solution for increasing the efficiency and accuracy of variant interpretation.

Available for trial/purchase in May 2018, VSClinical will allow labs to automate their clinical interpretation of variants based on ACMG Guidelines. This is a significant advancement to help eliminate the problems with human error and individual subjectivity. It will also reduce the time and effort required to sign off on clinical reports.

This product was funded by NIH grant 1R43GM128485-01. “We are grateful for the fact that the National Institute of General Medical Sciences agreed with our development and research plan and funded our work in this space,” says Dr. Andreas Scherer, CEO & President of Golden Helix. “In addition, numerous labs around the world gave us valuable feedback on our development work. I’d like to thank all of our contributors for their valuable support.”

Golden Helix will be demonstrating VSClinical live for the first time at the Annual Clinical Genetics Meeting (ACMG) in Charlotte, NC April 10-14, 2018. During these demonstrations, conference attendees will receive a complete understanding of VSClinical’s complete use of capabilities.

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years. Our innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing. With our solutions, hundreds of the world’s top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 1,200 peer-reviewed publications. For more information, visit

Source : Golden Helix, Inc.
Business Info :
Golden Helix, Inc.

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.